Gastrointestinal peptides exert important physiological roles in the control of feeding behavior, gut motility, nutrient absorption, and energy assimilation. Islet amyloid polypeptide is secreted from islet β‐cells, and exerts inhibitory actions on appetite, gastric motility, and glucagon secretion. Glucagon‐like peptide 1 (GLP‐1) is released from enteroendocrine cells and regulates food intake, gastric emptying, insulin and glucagon secretion, and β‐cell proliferation and apoptosis. Exendin‐4, a lizard‐derived peptide, is a potent and stable GLP‐1R agonist that exerts GLP‐1‐like actions
in vivo
. The overlapping glucose‐lowering properties of these peptides have fostered considerable interest in their development as new therapeutic agents for the treatment of diabetes mellitus.